To verify the efficacy and safety of the Aidi injection in Zusanli (ST 36) in the prevention and treatment in patients suffered from chemotherapy induced nausea and vomiting (chemotherapy induced nausea and vomiting, CINV) by the standardization of clinical research. Methods:A prospective, multicenter, randomized control clinical studies were carried out. A total of 90 patients were randomly divided into three groups of control group, normal saline group and Aidi injection group, with 30 cases in each group. The last two groups were given normal saline and Aidi injection in Zusanli (ST 36). The gastrointestinal toxicity reaction, anti-vomiting drug efficacy, life quality and safety were observed at day 1, 2, 3, 7 after chemotherapy. Results:The comparison of CINV among three groups from day 1 were statistically significant (P<005). From the degree level, it can be seen that Aidi injection group had lowest toxicity of digestive tract, followed by normal saline group. And the control group had the highest. The comparison of anti-vomiting drug efficacy among three groups from day 1 were statistically significant (P<005). According to the level of curative effect, the Aidi injection group had best curative effect, followed by normal saline group and control group. Compared with KPS score in the three groups, there was a statistically significant difference in Aidi injection group from day 3, and normal saline group and control group from day 2 (P<005), with a decreasing tendency. The improvement of KPS score in the three groups was statistically significant (P<005) from day 7 after chemotherapy. Conclusion:Aidi injection in Zusanli (ST 36) of both sides can effectively alleviate CINV, and can improve KPS scores, the quality of life of patients after chemotherapy, and with good safety.